Earnings Feed
Sign Up
Home/Filings/3/0001209191-21-048716
3//SEC Filing

BIOS Fund III QP, LP 3

Accession 0001209191-21-048716

CIK 0001740279other
View on SEC.govCompany Profile

Filed

Jul 28, 8:00 PM ET

Accepted

Jul 29, 9:37 PM ET

Size

24.7 KB

Accession

0001209191-21-048716

Insider Transaction Report

Form 3
Period: 2021-07-29
IN8BIO, INC.INAB
BIOS Capital Management, LP
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)
BIOS Advisors GP, LLC
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)
Fletcher Aaron G.L.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)
BIOS Fund III, LP
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)
BIOS Fund III NT, LP
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)
BIOS Fund III QP, LP
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (251,211 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (359,374 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,876,624 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (997,433 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (340,712 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (574,432 underlying)

  • Series A Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,225,316 underlying)
Footnotes (12)
  • [F1]Each share of Series A Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, has no expiration date and is expected to automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F10]The securities are directly held by Bios Fund III.
  • [F11]The securities are directly held by Bios Fund III QP.
  • [F12]The securities are directly held by Bios Fund III NT.
  • [F2]The securities are directly held by Bios Fund II, LP ("Bios Fund II").
  • [F3]Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
  • [F4]Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  • [F5]Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  • [F6]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
  • [F7]The securities are directly held by Bios Fund II QP.
  • [F8]The securities are directly held by Bios Fund II NT.
  • [F9]The securities are directly held by BIOS Incysus.

Documents

1 file

Issuer

IN8BIO, INC.

CIK 0001740279

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001791916

Filing Metadata

Form type
3
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 9:37 PM ET
Size
24.7 KB
View on SEC.gov